CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
Neoadjuvant Immunotherapy with Response-Adapted Treatment vs Standard-Of-Care Treatment For Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Selective Index Node Resection vs Lymph Node Dissection after Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma The Multicentre Selective Lymphadenectomy Trial-3 (MSLT-3)
Findings from the CCTG PR13/RADICALS-HD study confirm that adding two years, compared to six months of hormone therapy delays prostate cancer spread in people who had surgery to remove the prostate followed by radiotherapy.
BRC2 (E1505): A phase III randomized trial of adjuvant chemotherapy with or without bevacizumab for patients with completely resected stage IB (>/= 4 cm) – III a non-small cell lung cancer (NSCLC) trial. NCT00324805: Results are available on www.clinicaltrials.gov
During the Awards Ceremony at the CCTG Annual Spring meeting Dr. Lillian Siu was presented the Dr Joseph Pater Founder's Award for excellence in clinical trials research. The award is for recognizing a network clinical trials research investigator whose leadership and body of work has contributed to significant advances in the understanding, diagnosis, treatment, cure, and prevention of cancer.
Congratulations to the IND241 trial team at Princess Margaret Cancer Centre who were awarded the CCTG IND Team Award at the Annual Spring Meeting this past weekend. The team members include, David Cescon (QI), Julia Wang, Soha Ahrari, Irene Li, Simi Malhotra, Lindsay Muyot, Helia Purnaghshband, Carolina Sanabria Salas, Maria Ye, Divyalakshmi Babu, Jennifer Bornstein, Christine Cater, Julia D'Souza, Shirley Ho, Ansu Jomy Jose, Sul Hee Kim, Irum Mahmood, Alexis Maneja, Karla Moreira, Sam (sang pil) Park, and Rosa Pezzulli
CCTG presented Dr. Erica Tsang from Princess Margaret Cancer Centre the Dr. Elizabeth Eisenhauer Early Drug Development Young Investigator Award to recognize her work as a new investigator who has worked on IND projects and contributed significantly to the conduct of an IND trial at a member centre.
We are very honoured to present Jim Julian from McMaster University with the Excellence in Clinical Trials Conduct award which was graciously received by Jim at the CCTG Spring Meeting. The award is presented to an individual who exemplifies excellence in clinical trial operations and compliance.
"I would like to thank the CCTG and the DSMC Chair and Secretary for considering me for such an honour. I am happy to accept this recognition award.
The Phase III Team Award for CCTG-Led Trials was presented to the PR21 team from the BC Cancer at the Annual Spring Meeting this past weekend.
